Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health’s Colorectal Cancer Test, Guardant Reveal™ (PR Newswire)

Guardant Health has achieved a historic legal victory, securing $292.5 million, including $175.5 million in punitive damages, after a U.S. District Court jury found Natera guilty of false advertising and unfair competition. The case centered on claims that Natera misled oncologists about Guardant Reveal™, Guardant’s innovative MRD test for early-stage colorectal cancer, in favor of its competing product, Signatera™. The jury unanimously sided with Guardant and rejected all counterclaims by Natera.